Interleukin‐1 receptor antagonist gene polymorphism and mortality in patients with severe sepsis

This study aims to determine the influence of the polymorphism within the intron 2 of the interleukin‐1 receptor antagonist gene (IL‐1RN*) on the outcome of severe sepsis, and to assess its functional significance by correlating this polymorphism with the total production of interleukin‐1 receptor antagonist (IL‐1Ra) protein determined in stimulated peripheral blood mononuclear cells (PBMC). A group of 78 patients with severe sepsis (51 survivors and 27 nonsurvivors) was compared with a healthy control group of 130 blood donors, and 56 patients with uncomplicated pneumonia. We found a significant association between IL‐1RN* polymorphism and survival. Thus, after adjusting for age and APACHE II score, multiple logistic regression analysis showed that patients homozygotes for the allele *2 had a 6·47‐fold increased risk of death (95% CI 1·01–41·47, P = 0·04). Besides, compared with patients homozygous or heterozygous for the allele *1, IL‐1RN*2 homozygotes produced significantly lower levels of IL‐1Ra from their PBMC. Our results suggest that insufficient production of this cytokine might contribute, among other factors, to the higher mortality rate found in severe sepsis patients with the IL‐1RN*2 homozygous genotype.

[1]  N. Camp,et al.  Association of the interleukin 1 receptor antagonist gene with ulcerative colitis in Northern European Caucasians , 2001, Gut.

[2]  J. Renart,et al.  Greater diversity than previously thought of chromaffin cell Ca2+ channels, derived from mRNA identification studies , 2000, FEBS letters.

[3]  J. Renart,et al.  Predictive Value of Nuclear Factor κB Activity and Plasma Cytokine Levels in Patients with Sepsis , 2000, Infection and Immunity.

[4]  J. Dhainaut,et al.  Association of TNF2, a TNF-alpha promoter polymorphism, with septic shock susceptibility and mortality: a multicenter study. , 1999, JAMA.

[5]  A. Hoeft,et al.  Comparison of two polymorphisms of the interleukin-1 gene family: interleukin-1 receptor antagonist polymorphism contributes to susceptibility to severe sepsis. , 1999, Critical care medicine.

[6]  M. Hurme,et al.  Gene polymorphisms of interleukins 1 and 10 in infectious and autoimmune diseases. , 1998, Annals of medicine.

[7]  M. Hurme,et al.  IL‐1 receptor antagonist (IL‐1Ra) plasma levels are co‐ordinately regulated by both IL‐1Ra and IL‐1β genes , 1998 .

[8]  C. Dinarello,et al.  Proinflammatory and anti-inflammatory cytokines as mediators in the pathogenesis of septic shock. , 1997, Chest.

[9]  S. Hollerbach,et al.  Imbalance of the interleukin 1 system in colonic mucosa—association with intestinal inflammation and interleukin 1 receptor agonist genotype 2 , 1997 .

[10]  S. Endres,et al.  Lack of association between an interleukin-1 receptor antagonist gene polymorphism and ulcerative colitis. , 1997, Gut.

[11]  F. Stüber,et al.  A genomic polymorphism within the tumor necrosis factor locus influences plasma tumor necrosis factor-alpha concentrations and outcome of patients with severe sepsis. , 1996, Critical care medicine.

[12]  D. Grennan,et al.  Cytokine production by normal human monocytes: inter‐subject variation and relationship to an IL‐1 receptor antagonist (IL‐1Ra) gene polymorphism , 1995, Clinical and experimental immunology.

[13]  Á. Hernanz,et al.  Cell-mediated immune response and cytokine production in idiopathic senile anorexia , 1994, Mechanisms of Ageing and Development.

[14]  C. Gordon,et al.  Interleukin-1 receptor antagonist gene polymorphism as a disease severity factor in systemic lupus erythematosus. , 1994, Arthritis and rheumatism.

[15]  A. Blakemore,et al.  Polymorphism in human IL-1 receptor antagonist gene intron 2 is caused by variable numbers of an 86-bp tandem repeat , 1993, Human Genetics.

[16]  W. Knaus,et al.  Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. , 1992, Chest.

[17]  E. Draper,et al.  APACHE II: A severity of disease classification system , 1985, Critical care medicine.

[18]  S. V. Deventer,et al.  Cytokine and cytokine receptor polymorphisms in infectious disease , 2000, Intensive Care Medicine.

[19]  A. Hill,et al.  The immunogenetics of human infectious diseases. , 1998, Annual review of immunology.

[20]  B. Taylor,et al.  Prediction of outcome from intensive care: a prospective cohort study comparing Acute Physiology and Chronic Health Evaluation II and III prognostic systems in a United Kingdom intensive care unit. , 1997, Critical care medicine.

[21]  D. Grennan,et al.  Lack of association between an interleukin-1 receptor antagonist gene polymorphism and systemic lupus erythematosus. , 1995, Disease markers.